CD8A and neoplasm: Accordingly, the companion reports by Andrews et al. and Cillo et al.2,3 extent on this finding of recalibrated tumor immunosurveillance by CD8+ T cells after combined anti-PD-1/anti-LAG-3 treatment by demonstrating increased response to IFNγ in addition to TCR signaling.